Mori Hiroyoshi, Jinnouchi Hiroyuki, Diljon Chahal, Torii Sho, Sakamoto Atsushi, Kolodgie Frank D, Virmani Renu, Finn Aloke V
CVPath Institute, Gaithersburg, MD 20878, USA.
University of Maryland, School of Medicine, Baltimore, MD 21201, USA.
Future Cardiol. 2018 May 1;14(3):225-235. doi: 10.2217/fca-2017-0103. Epub 2018 Mar 27.
The COBRA-PzF™ (CeloNova BioSciences, Inc., TX, USA) is a new type of coronary stent composed of a cobalt chromium metallic backbone surrounded by a nanothin layer of Polyzene-F (PzF) without any added drug. Evidence from basic studies supports antithrombotic and anti-inflammatory properties for the PzF surface coating. Preclinical studies support the thromboresistance of PzF-coated surfaces and clinical studies have shown good outcomes for patients receiving this device with very low rates of stent thrombosis. COBRA-PzF may be especially useful in patients at high risk for bleeding. Ongoing clinical trials will determine whether shortening the duration of dual antiplatelet therapy to less than 1 month is feasible and these data may represent a new paradigm with regards to patients at high risk for bleeding.
COBRA-PzF™(美国得克萨斯州的CeloNova生物科学公司)是一种新型冠状动脉支架,由钴铬金属骨架构成,其周围环绕着一层不含任何添加药物的聚烯-F(PzF)纳米薄层。基础研究证据支持PzF表面涂层具有抗血栓形成和抗炎特性。临床前研究支持PzF涂层表面的抗血栓性,临床研究表明接受该装置的患者预后良好,支架血栓形成率极低。COBRA-PzF在出血高危患者中可能特别有用。正在进行的临床试验将确定将双联抗血小板治疗时间缩短至不到1个月是否可行,这些数据可能代表出血高危患者的一种新范例。